RCM
CRVS icon

RA Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

RA Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.72M Hold
450,000
– – 0.06% 79
2026
Q1 		$6.58M Buy
+450,000
New +$7.18M 0.07% 79

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RA Capital Management's CRVS Position: Q2 2026 in Review

RA Capital Management held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 450,000 shares worth $6.72M. The position accounts for 0.06% of the portfolio, ranked #79.

RA Capital Management first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • RA Capital Management held 450,000 shares of Corvus Pharmaceuticals worth $6.72M as of Q2 2026.
  • RA Capital Management left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
  • Corvus Pharmaceuticals made up 0.06% of RA Capital Management's portfolio in Q2 2026, its #79 holding.
  • RA Capital Management first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.